About: Serum soluble receptor for advanced glycation end‐products during acute bronchiolitis in infant: Prospective study in 93 cases

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Serum soluble receptor for advanced glycation end‐products during acute bronchiolitis in infant: Prospective study in 93 cases Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Serum soluble receptor for advanced glycation end‐products during acute bronchiolitis in infant: Prospective study in 93 cases
Creator	Labbé, André Egron, Carole Laurence, \| Jabaudon, Matthieu Sapin, Vincent Aurélien Mulliez, \| Coste, Karen Emmanuelle, \| Pharm, Roszyk Phd, Rochette
source	Medline; PMC
abstract	INTRODUCTION: Acute bronchiolitis is a major cause of acute respiratory distress in infants. The soluble receptor for advanced glycation end‐products (sRAGE) is a biomarker of pulmonary damage processes, with a diagnostic and a prognostic value in acute respiratory distress syndrome (ARDS). The RAGE pathway is also implicated in the pathogenesis of other respiratory diseases like asthma, but the value of sRAGE levels in acute bronchiolitis remains under‐investigated. MATERIAL AND METHODS: A prospective, observational, and analytical study was conducted at Clermont‐Ferrand University Hospital. The main objective was to evaluate the correlation between serum sRAGE and clinical severity of bronchiolitis in hospitalized infants aged <1 year. We analyzed correlations between serum sRAGE and Wainwright score, short‐term morbidity attributable to bronchiolitis, causal viruses and risk for recurrent wheezing at 1 year. RESULTS: The study included 93 infants. sRAGE levels were significantly lower in acute bronchiolitis patients (mean 1101 pg/mL) than in controls (2203 pg/mL, P < 0.001) but did not correlate with clinical severity. No correlation was found between serum sRAGE and severity score, respiratory viruses, and recurrent wheezing at 1 year. Serum sRAGE levels were negatively correlated with age (r = −0.45, P < 0.001). CONCLUSION: Serum sRAGE levels are decreased in acute bronchiolitis but not correlated with disease severity. sRAGE levels should be age‐adjusted in infants. Serum sRAGE levels measured in the setting of acute bronchiolitis were not predictive of recurrent wheezing.
has issue date	2018-08-16(xsd:dateTime)
bibo:doi	10.1002/ppul.24141
bibo:pmid	30113140
has license	no-cc
sha1sum (hex)	6a47313d7fb53f6fa7fe4834df9bb80636458dfc
schema:url	https://doi.org/10.1002/ppul.24141
resource representing a document's title	Serum soluble receptor for advanced glycation end‐products during acute bronchiolitis in infant: Prospective study in 93 cases
has PubMed Central identifier	PMC7167909
has PubMed identifier	30113140
schema:publication	Pediatr Pulmonol
resource representing a document's body	covid:6a47313d7fb53f6fa7fe4834df9bb80636458dfc#body_text
is schema:about of	named entity 'levels' named entity 'respiratory diseases' named entity 'bronchiolitis' covid:arg/6a47313d7fb53f6fa7fe4834df9bb80636458dfc named entity 'bronchiolitis' named entity 'acute bronchiolitis' named entity 'asthma' named entity 'virus' named entity 'adenovirus' named entity 'cough' named entity 'enterovirus' named entity 'acute bronchiolitis' named entity '0.9' named entity 'lithium' named entity 'Chest X-ray' named entity 'multivariate analysis' named entity 'bronchiolitis' named entity 'prognosis' named entity 'apnea' named entity 'multiplex PCR' named entity 'Nasopharyngeal swab' named entity 'crackles' named entity 'atopic' named entity 'acute bronchiolitis' named entity 'pro-inflammatory' named entity 'wheezing' named entity 'acute bronchiolitis' named entity 'asthma' named entity 'bronchiolitis' named entity 'serum' named entity 'cow's milk protein allergy' named entity 'corticosteroids' named entity 'intensive care unit' named entity 'wheezing' named entity 'family history' named entity 'serum' named entity 'reverse transcription-polymerase chain reaction' named entity 'bronchopulmonary dysplasia' named entity 'blood samples' named entity 'family history' named entity 'atelectasis' named entity 'atelectasis' named entity 'pediatrician' named entity 'P-value' named entity '0.45' named entity 'pediatric' named entity 'Rhinovirus' named entity 'surgical intervention' named entity 'ligands' named entity 'wheezing' named entity 'correlated negatively' named entity 'chromatography' named entity 'pulmonary disease' named entity 'prematurity' named entity 'Mycoplasma pneumoniae' named entity 'oxygen saturation' named entity 'urine samples' named entity 'serum' named entity 'extracellular' named entity 'parenteral' named entity 'Salido' named entity 'physiotherapy' named entity 'case-control' named entity 'Bordetella pertussis' named entity 'serum' named entity 'wheezing' named entity 'serum' named entity 'kinetics' named entity 'respiratory support' named entity 'superinfection' named entity 'inflammation' named entity 'infectious process'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software